We conducted a retrospective review of the records of 23 patients who had been diagnosed with regionally metastatic head and neck squamous cell carcinoma from an unknown primary tumor. Our goal was to assess the utility of panendoscopy in locating the primary tumor in those patients whose positron-emission tomography/computed tomography (PET/CT) fi ndings were negative. Overall, we found that PET/CT had correctly identifi ed the unknown primary in 12 of the 23 patients (52%); panendoscopy confi rmed this fi nding in all 12. Of the remaining 11 patients, however, panendoscopy located the primary tumor in only 1 (9%). In this era of cost containment and ongoing advances in imaging and transnasal esophagoscopy, it is important to revisit the workup of an unknown primary in patients with a negative PET/CT scan. Th ere are various advantages and disadvantages to performing panendoscopy with biopsy in patients with an unknown primary and a negative PET/CT scan, but our results and the fi ndings of others indicate that it will detect the primary in only about 10% of these cases. We recommend careful selection of patients who are to undergo panendoscopy for the routine workup of an unknown primary.
Introduction
Th e failure to detect the location of the primary tumor in a patient with metastatic head and neck cancer poses a clinical challenge that can aff ect the course of treatment and disease prognosis. In 1944, Martin and Morfi t described the fi rst case of an unknown primary in a patient with a cervical lymph node metastasis. 1 In 1995, Abbruzzese and Raber defi ned patients with an unknown primary as those who have been determined to have a biopsy-proven metastatic carcinoma and whose routine clinical workup fails to detect an anatomic origin. 2 Th e reported incidence of unknown primary tumors in the head and neck ranges from 1 to 9% of all head and neck cancers. [3] [4] [5] [6] Th e inability to fi nd a primary tumor is problematic because tumor behavior and appropriate therapy can be best predicted on the basis of the primary's location. 7 Once a patient has been found to have a biopsy-proven metastatic squamous cell carcinoma of the head and neck, the typical workup to fi nd the primary tumor involves a thorough head and neck examination, fi beroptic laryngoscopy and nasopharyngoscopy, chest x-ray, and highresolution computed tomography (CT) of the head and neck. 8 In addition, a panendoscopic examination with general anesthesia can be performed to obtain random biopsies of the most likely sites that might harbor an unknown primary (i.e., the nasopharynx, tonsils, tongue base, and piriform sinuses), as well as biopsies of any abnormalities noted on diagnostic studies or any suspi-• fi beroptic transnasal endoscopy of the nasal cavity, nasopharynx, oropharynx, hypopharynx, and larynx;
• standard posteroanterior and lateral chest x-rays; and
• contrast-enhanced high-resolution CT of the neck.
Following this workup, all patients had undergone 2-[18 F]fl uoro-2-deoxy-D-glucose (FDG) PET/CT in adherence with a strict protocol. Patients were required to fast overnight and refrain from smoking. Each patient's fasting fi nger-stick blood glucose level was confi rmed to be less than 200 mg/dl on the day of the scan. All patients received oral and intravenous hydration with approximately 18 oz of water and 250 ml of normal saline, respectively. FDG was administered intravenously in a dose of approximately 15 mCi. Some 15 minutes aft er FDG infusion, patients received 10 mg of furosemide intravenously, and approximately 75 minutes later, dedicated PET/CT images were obtained from the skull base to the mid-thigh. For the PET/CT studies, lowdose, noncontrast CT images were used for attenuation correction and anatomic localization. PET/CT images were evaluated by an experienced nuclear medicine physician (D.L.) who was aware that the primary was unknown and thus was aggressive in interpreting even very subtle asymmetries in FDG uptake in order to identify the primary site.
Following PET/CT, patients had been taken to the operating room for an examination under general anesthesia and panendoscopy with biopsies. Directed biopsies were taken at the appropriate site for patients whose PET/CT scans had identifi ed the site of disease. All other patients had undergone random biopsies of the nasopharynx, base of the tongue, and piriform sinuses, as well as any suspicious mucosal lesions seen on endoscopy. In addition, at least an ipsilateral tonsillectomy was performed on those patients who had not previously undergone a tonsillectomy and who had adequate lymphoid tissue in the tonsillar fossa. All specimens were evaluated by an experienced pathologist. Th e sensitivity, specifi city, positive predictive value, and negative predictive value of PET/CT in identifying an unknown primary tumor were calculated.
We also conducted an analysis of the costs of performing a panendoscopy with pathologic evaluation and compared them with Medicare reimbursement rates. Th e hospital, surgeon, and anesthesia costs for a 1-hour panendoscopy with or without tonsillectomy were obtained from our institution, the Louisiana State cious mucosal lesions seen on endoscopy. 9 An ipsilateral tonsillectomy has also been suggested for patients who have suffi cient lymphoid tissue in the tonsillar fossa; 2 studies have found success rates of 10 10 and 26%. 11 Whole-body positron-emission tomography (PET) with CT (PET/CT) has become increasingly reported as a way of identifying the site of a primary tumor and evaluating the possibility of other unknown tumors. 5, 6 Th e sensitivity and specifi city of PET/CT in detecting unknown primaries has been reported to be approximately 88 and 75%, respectively. 12 In addition, the success rate of PET/CT in detecting a primary tumor previously undetected by a typical workup has been reported at approximately 25%. 12 With a comprehensive approach, a primary tumor can be discovered in more than 90% of cases. 8 In the remaining cases, management is geared toward treating the neck as well as the most likely sites to harbor an unknown primary. In such patients, treatment includes curative radiation to the nasopharynx, oropharynx, and neck bilaterally. For those patients who exhibit extensive lymph node involvement or residual disease following radiation, neck dissection is indicated. 9 Many investigators have looked at the effi cacy of PET/CT in detecting primary tumors in patients who present with a cervical lymph node metastasis from an unknown primary. 3, 5, 6 However, as far as we know, there have been no published studies to determine the effi cacy of panendoscopy in detecting primary tumors when PET/CT and other radiologic and clinical modalities have failed to do so. We conducted a study to revisit the traditional workup of patients with an unknown primary tumor and a negative PET/CT scan with emphasis on the utility of panendoscopy in this regard.
Patients and methods
For this retrospective study, we reviewed the PET/CT database at the Biomedical Research Foundation in Shreveport, La., to identify patients who had undergone PET/CT aft er being diagnosed with a cervical nodal metastasis and a clinically unknown primary tumor from January 2001 through December 2005. For a patient to be eligible for this study, the fi nding of a metastatic squamous cell carcinoma must have been made on fi neneedle aspiration by a cytologist, and the location of the primary tumor must have remained unknown despite a thorough workup that included the following:
• a comprehensive history and physical examination of the head and neck; University Health Sciences Center, Shreveport. Th e hospital and physician costs for performing both frozen and permanent pathologic evaluations of specimens were also obtained.
Th e study protocol was approved by our facility's Institutional Review Board.
Results
Overall, 23 patients-18 men and 5 women, aged 45 to 81 years (mean: 59.0)-satisfi ed all the inclusion criteria for our study. Th e group's node status according to TNM category is shown in the table. Findings:
• PET/CT was positive in 14 patients (61%) and negative in 9 (39%).
• Panendoscopy was positive in 13 patients (57%) and negative in 10 (43%).
• Panendoscopy confi rmed the location of the primary tumor in 12 of the 14 PET/CT-positive patients (86%).
• Based on the panendoscopic fi ndings, PET/CT yielded a true-positive result in 12 of the 23 patients (52%), a false-positive result in 2 patients (9%), and a false-negative result in 1 of 9 (11%). PET/CT placed both of the false positives in the palatine tonsil.
• When the 2 PET/CT false-positives were accounted for, panendoscopy detected only 1 of 11 unknown primaries (9%) that had not been detected by PET/CT. Th is lesion was a small (~5 mm) focus of mucosal irregularity located in the base of the tongue.
• Th e sensitivity of PET/CT was 92%, its specifi city was 80%, its positive predictive value was 86%, and its negative predictive value was 89%. Th e 95% confi dence interval (CI) for the negative predictive value is fairly broad: 52 to 100%.
• No complications occurred during the acquisition of PET/CT, nor did PET/CT detect any additional metastasis or synchronous second tumor in any patient.
Among the 12 cases in which PET/CT yielded a true-positive result, 6 primaries were located in the palatine tonsil, 4 at the base of the tongue, 1 in the fl oor of the mouth, and 1 in the hypopharynx. In 8 of these 12 cases, the location of the primary tumor was obvious on panendoscopy; in the remaining 4 patients, the primary was more diffi cult to locate. In fact, in these 4 cases, the identifi cation of the primary was actually more attributable to the imaging than to the panendoscopy. Th e highly suspicious PET/CT fi ndings allowed for a narrowly targeted panendoscopic examination and a deeper-than-normal biopsy. Otherwise, these primaries might have been missed.
Of the 6 tonsil primaries, 3 were fi rm on palpation and 1 had a friable area in the superior pole. In all 6 of these cases, the patient would have undergone a tonsillectomy as part of his/her panendoscopic procedure, and the primary tumor in each case would probably have been identifi ed even without PET/CT because of a strong clinical suspicion. However, pathologists make random sections through tonsils, and it is possible that a small focus would have been missed in such cases. We advised the pathologist of our high degree of clinical suspicion based on PET/CT in these cases, and that notifi cation might have prompted a more detailed exploration of the suspicious tonsil.
Th e total hospital, surgeon, and anesthesia cost for a 1-hour panendoscopy with or without tonsillectomy at our institution at the end of this study was $2,502. In addition, hospital and physician costs were $125 and $150, respectively, for a frozen pathologic evaluation and $80 and $225, respectively, for a permanent pathologic evaluation, bringing the total cost for performing both pathologic evaluations to $580. Th erefore, the total cost for performing the panendoscopy and pathology was $3,082. Medicare reimbursement rates for costs incurred while performing a 1-hour panendoscopy with or without tonsillectomy were determined to be $877 for the hospital, $500 for the surgeon, and $1,250 for the anesthesia, for a total of $2,627. Th erefore, the diff erence between the cost of each procedure and the amount reimbursed by Medicare was $455. Also, the Medicare reimbursement rate for PET/CT is approximately $2,500.
Discussion
Since the introduction of PET/CT, many studies have looked at its effi cacy in detecting primary tumors in patients who present with cervical lymph node metastasis from an unknown primary tumor. Th e fairly high sensitivity and specifi city of PET/CT in detecting unknown primaries make it a useful tool in the diagnosis Th e purpose of the present study was to revisit the traditional workup of an unknown primary in a patient with a negative PET/CT, with emphasis on the utility of panendoscopy. Although the number of patients in our study was small (n = 23), our fi ndings were similar to those reported in two meta-analyses that evaluated the effi cacy of PET/CT in detecting unknown primary head and neck tumors in a total of 481 patients. 12, 13 We found that PET/CT had a fairly high negative predictive value (89%) and a low false-negative rate (11%). Th ese fi gures compare favorably with the results of the combined meta-analyses, which yielded a negative predictive value of 90% and a false-negative rate of 10%. 12, 13 It is important to note that an unknown primary is not common in patients with head and neck cancers (1 to 9% of cases), and hence a single investigation is always limited by a small study population. 3 Th e 95% CI for the negative predictive value of 89% for PET/ CT in our study was 52 to 100%, a fi gure that was based on a small number of patients (n = 9) who had a negative scan. However, in the previously mentioned meta-analyses that included a total of 481 patients, the 95% CI for a negative predictive value of 90% was 87 to 93%. 12, 13 Th is range is obviously much narrower, but it still encompasses the 89% fi nding in our study. Given these values, we can conclude that panendoscopy with biopsy will benefi t only about 10% of patients with an unknown primary head and neck carcinoma following a negative PET/CT scan.
Th e question then arises: Is it benefi cial for a patient with an unknown primary and a negative PET/CT result to undergo panendoscopy with biopsy? To arrive at an answer, we must take into consideration the availability of other diagnostic and treatment options, the risk of complications, the associated costs, and the possibility that a second primary might be present.
Obviously, panendoscopy with biopsy in these patients has its advantages and disadvantages. For the 10% of patients who would benefi t, treatment includes focused radiation to the primary site. For patients in whom the primary is not found, however, treatment involves elective irradiation to the most likely mucosal sites where tumors occur. Th e major disadvantage for these patients is the additional morbidity associated with irradiating a larger area. Complications such as mucositis, odynophagia, dysphagia, hoarseness, xerostomia, osteoradionecrosis, and fi brosis are more likely to occur with extended-fi eld radiotherapy.
A major advantage to performing panendoscopy with biopsy is the possibility that it might detect a second primary tumor. A review of 20 studies of multiple primary malignancies found that the incidence of multiple primaries in the head and neck ranged between 1.4 and 17%. 14 Furthermore, studies that have looked at the effi cacy of panendoscopy with biopsy in detecting an unsuspected second primary found that discovery rates ranged between 6 and 58%. 8, 15, 16 However, other studies found much lower rates of discovery: 1.5 17 and 1.9%. 18 One of the biggest disadvantages of panendoscopy with biopsy is the cost involved. Levine and Nielsen reported that the approximate cost of performing a panendoscopy with biopsy as a day-surgery procedure without an overnight hospital stay is approximately $2,000, plus or minus about $500. 14 In our study, we found that the total cost was roughly $3,100.
Finally, while the complication rate associated with panendoscopy is very small (1%), 14 any procedure that involves general anesthesia carries a risk for patients with medical comorbidities.
Perhaps the best diagnostic alternative to panendoscopy available at this time is transnasal esophagoscopy (TNE). TNE has been shown to be safe and well tolerated, and it can be performed in an offi ce setting without sedation. 19 Moreover, TNE allows the physician to easily visualize the entire upper aerodigestive tract, and it is suitable for performing laryngoscopy and bronchoscopy with or without biopsies. 19 In one study that compared panendoscopy with TNE in the diagnosis of known lesions of the head and neck, the diagnosis rates were identical. 20 It is necessary to reproduce these fi ndings in other studies and to compare TNE's effi cacy in detecting unknown primary tumors before TNE can replace panendoscopy in the routine workup of patients with an unknown primary and negative PET/CT result.
In conclusion, in this era of cost containment and in view of ongoing advances in imaging and TNE, it is important to revisit the traditional workup for an unknown primary in a patient with a negative PET/CT scan. Our study and others 12, 13 have shown that PET/ CT has a fairly high negative predictive value in patients with unknown primary head and neck cancer. As a result, the benefi t of routine panendoscopy with biopsy in these patients may be questionable. Before a patient is subjected to a panendoscopy, the clinician must take into consideration the availability of other diagnostic and treatment options, the risk of complications, the associated costs, and the possibility that a second primary might be present. Another consideration is the fact that panendoscopy detects the unknown primary
